Photo of David T. Ting, MD

David T. Ting, MD


Accepting New Patients





Medical Education
  • MD, Harvard Medical School
  • Residency, Massachusetts General Hospital
  • Fellowship, Dana Farber Cancer Institute
Board Certifications
  • Internal Medicine
  • Medical Oncology
  • Boston: Massachusetts Eye and Ear Infirmary
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Connecticut
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group

Edit Profile

News & Events

  • Mass. General study reveals gene expression patterns in pancreatic circulating tumor cells

    Analysis of circulating tumor cells in a mouse model of pancreatic cancer identified distinct patterns of gene expression in several groups of CTCs, including significant differences from the primary tumor that may contribute to the ability to generate metastases and prove to be targets for improved treatment of the deadly tumor.

  • Physicians and Physicists Join Forces to Fight Pancreatic Cancer

    A team of physicians and physicists are collaborating on a mission to solve the riddle of pancreatic cancer, one of medicine’s most lethal malignancies. The pancreatic-cancer convergence team has a plan to mount a clinical trial to test a new hypothesis: that treatment with synthetic vitamin D can make treatment-resistant pancreas tumors vulnerable to a patient’s immune system. David T. Ting, MD, a medical oncologist at Massachusetts General Hospital Cancer Center, is part of this innovative approach to fight pancreatic cancer.


55 Fruit Street
Boston MA, 02114-2696
Phone: 617-724-4000

Edit Profile

Back to Top